EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access · CC BY 4.0

Approach to the patient: precision medicine–guided evaluation and treatment of acromegaly

Manel Puig-Domingo iD, Montserrat Marques-Pamies, Miguel Sampedro, Joan Gil iD, Marta Araujo-Castro iD, Rebeca Martínez-Hernández, Betina Biagetti iD, Mireia Jordà, Elena Valassi iD, Mónica Marazuela

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgag241 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Manel Puig-Domingo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology and Nutrition Service, Hospital Universitari Germans Trias i Pujol, Badalona 08916, Spain. Hauptthemen laut MEDLINE: Acromegaly, Adenoma, Growth Hormone-Secreting Pituitary Adenoma, Precision Medicine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union, EU, Instituto Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acromegaly is a heterogeneous disease in which delayed biochemical control remains common despite the availability of multiple therapeutic options. Traditional stepwise medical treatment algorithms often rely on the use of first-generation somatostatin receptor ligands (fgSRLs) as first-line drugs with empirical escalation and trial-and-error approaches, prolonging patients' exposure to hormonal excess. Cluster analyses indicate that overall, 3 main classes of patients with acromegaly representing distinct biological phenotypes can be recognized: (1) young patients with invasive macroadenomas and frequent resistance to fgSRLs; (2) older patients with noninvasive tumors and SRL responsiveness in the majority of them; and (3) patients with intermediate features often requiring combination medical therapy in whom prediction of response is more challenging. From a practical perspective, biomarker-guided treatment selection based on T2-weighted magnetic resonance imaging signal intensity, the short acute octreotide test, and tumor immunohistochemistry, following the strategy validated in the ACROFAST study, is applicable in clinical practice. It allows prompt biochemical control and tumor volume reduction, a rationale leading to superior effectiveness performance than the classic sequencing therapy involving the universal utilization of fgSRLs as first option. In the era of integrative and participative medicine, such a protocol enables the early identification of most patients unlikely to respond to fgSRLs, thus supporting timely initiation of pegvisomant, pasireotide, or combination therapy, and the achievement of hormonal control in nearly 80% of patients. Conclusion Precision medicine has become a practical reality in acromegaly. A biomarker-guided strategy improves therapeutic efficiency and should be incorporated into contemporary clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcromegalyAdenomaGrowth Hormone-Secreting Pituitary AdenomaPrecision MedicineHumansMagnetic Resonance ImagingOctreotideReceptors, SomatostatinSomatostatinTreatment Outcome

Stichwörter der Autor:innen

acromegalybiomarkersfunctional testsimagingmolecular profilingprecision medicine

Substanzen

OctreotideReceptors, SomatostatinSomatostatin

Autor:innen und Institutionen

  • Endocrinology and Nutrition Service, Hospital Universitari Germans Trias i Pujol, Badalona 08916, Spain.
  • Endocrine Tumors Research Group, Germans Trias i Pujol Research Institute, Badalona 08916, Spain.
  • Department of Medicine, Universitat Autònoma de Barcelona, Campus de can Ruti, Badalona 08916, Spain.
  • Endocrinology and Nutrition Service, Hospital de Granollers, Granollers 08402, Spain.
  • Endocrinology and Nutrition Service, Hospital Universitario la Princesa, Madrid 28006, Spain.
  • CIBERER Group 747, Instituto de Salud Carlos III, Madrid 28029, Spain.

ORCID-Profile: Manel Puig-Domingo, Joan Gil, Marta Araujo-Castro, Betina Biagetti, Elena Valassi

Förderung

  • European Union
  • EU
  • Instituto Carlos III

Zitieren

APA

Puig-Domingo, M., Marques-Pamies, M., Sampedro, M., Gil, J., Araujo-Castro, M., Martínez-Hernández, R., Biagetti, B., Jordà, M., Valassi, E., & Marazuela, M. (2026). Approach to the patient: precision medicine–guided evaluation and treatment of acromegaly. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag241

Vancouver

Puig-Domingo M, Marques-Pamies M, Sampedro M, Gil J, Araujo-Castro M, Martínez-Hernández R, et al. Approach to the patient: precision medicine–guided evaluation and treatment of acromegaly. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag241

BibTeX
@article{PuigDomingo2026,
  author = {Puig-Domingo, Manel and Marques-Pamies, Montserrat and Sampedro, Miguel and Gil, Joan and Araujo-Castro, Marta and Martínez-Hernández, Rebeca and Biagetti, Betina and Jordà, Mireia and Valassi, Elena and Marazuela, Mónica},
  title = {Approach to the patient: precision medicine–guided evaluation and treatment of acromegaly},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgag241}
}
Kostenlos starten →